AFT Pharmaceuticals Ltd., a pharmaceutical company, intends to issue 11.9 million shares at a price of NZD2.8 per share, to raise gross proceeds of NZD33.2 million in an initial public offering. The trustees of the Atkinson Family Trust, associated with founder Hartley Atkinson and wife Marree, will raise NZD3 million selling their stake down to 76
Release date- 24112015- Paris and Tarrytown, New York- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular benefits of Praluent Injection after an acute coronary syndrome.
By a News Reporter-Staff News Editor at Women's Health Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Gainer, Erin; Ulmann, Andre; Massart, Luc; Guillard, Helene, filed on December 11, 2009, was published online on November 10, 2015. The patent's assignee for patent number 9180131 is LABORATOIRE HRA PHA
Analysis from business intelligence provider GBI Research- Life Cycle Management Strategies- Optimizing revenues and defending generic competition- says that it is becoming increasingly important for pharmaceutical companies to implement suitable life cycle management strategies in order to maximize revenues and the lifespan of their portfolios..
The changing landscape of the U.S. health care system has resulted in rising costs for prescription medications, causing a real health and financial burden for many Americans. According to the Generic Pharmaceutical Association, generic medications can cost 30 to 80 percent less than their brand-name counterparts. In 2014, the FamilyWize Prescrip
Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and develop
Woodbridge, Ontario/ TheNewswire/ November 25, 2015- Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that it received Notification Number NN.F7C1 for BeneFishial (TM) Pet from the Low Risk Veterinary Health Products Interim Notification Program.
China Nepstar Chain Drugstore Ltd., a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2015.. Same store sales increased by 13.2% compared to the third quarter of 2014 Revenue increased by 7.4% to RMB793.0 million comp
The Food and Drug Administration on Monday appealed for more public participation in the fight against the proliferation of counterfeit medicines. "Participation of the society is vital to win this fight, said Dr. Hartigan-Go in a forum held Monday at Acacia Hotel in Alabang, Muntinlupa City as he cited the detrimental effects of counterfeit medic
Developmental, commercial, and regulatory/legal strategies all play a key role in boosting the profitability of pharmaceutical products, says GBI Research.. Analysis from business intelligence provider GBI Research- Life Cycle Management Strategies- Optimizing revenues and defending generic competition- says that it is becoming increasingly...
It is an abridged version of the Company s full Half Year report for the six months ended 30 September 2015. The Company's Half Year Report& Accounts for the six months ended 30 September 2015 has been submitted to the UK Listing Authority, and will shortly be available for inspection on the National Storage Mechanism: www.hemscott.com/nsm. do.
TARRYTOWN, New York and PARIS, Nov. 24, 2015/ PRNewswire/ Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular benefits of Praluent Injection after an acute coronary syndrome.
Sanofi and Regeneron Announce 18,000- Patient ODYSSEY OUTCOMESTrial of Praluent Injection Fully Enrolled Paris and Tarrytown, New York- November 24, 2015- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potenti
LONDON- AstraZeneca PLC said Monday it has agreed to sell the US rights to its Crohn's disease medicine Entocort to Irish over-the-counter pharmaceuticals manufacturer Perrigo Co PLC for up to USD380 million. AstraZeneca said that US product sales of Entocort were USD89 million in the first nine months of 2015. The sale is expected to complete by t
By a News Reporter-Staff News Editor at Clinical Trials Week Exelixis, Inc. announced that the U.S. Food and Drug Administration has approved COTELLIC? as a treatment for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with vemurafenib. COTELLIC is a selective inhibitor of MEK that was disc
Table of Contents Office of the Federal Register Agriculture Department SeeFood and Nutrition Service Army Department NOTICES Exclusive Patent Licenses: MalarVx, Inc., 72954 Centers for Medicare& Medicaid Services NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals, 72968-72969 Children and Families...
'This submission to the FDA is evidence of Janssen's continued commitment to bringing forth new treatment options for people with type 2 diabetes,' said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular& Metabolism, Janssen.' We look forward to working with the FDA to bring this combination therapy to adult patients with type 2
On July 10, 2015, SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, announced it had initiated coverage of Nutra Pharma Corporation with a Price Target of $0.53 per share. On July 15, 2015 we announced that we had filed an application with the FDA for orphan drug status
Over-the-counter and prescription drug maker Perrigo is acquiring the U.S. rights to an AstraZeneca drug line for Crohn's disease for $380 million. Dublin- based Perrigo, which has its North American headquarters in Allegan, said today that it will acquire Entocort, or budesonide, prescription capsules as well as the authorized generic capsules mar
Perrigo Company plc announced today that it will acquire Entocort capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals within the U.S. from AstraZeneca plc for $380 million. Perrigo Chairman and CEO Joseph C. Papa commented, "We are extremely excited to acquire Entocort from a world-class organization such as
M Pharmaceutical, Inc.,, today announced it has entered into a letter of intent to acquire assets from Chelatexx, LLC related to a reformulated version of orlistat. Indicative terms of the letter of intent include an up-front cash payment, 10 million common shares of M Pharmaceutical, and a low single-digit royalty on net sales. Matthew Lehman, CEO
SUMMARY: The Food and Drug Administration is announcing the availability of a draft guidance for industry entitled "Sunscreen Innovation Act: Withdrawal of a 586 A Request or Pending Request." The recommendations in this guidance apply to 586 A requests and pending requests that seek a determination from FDA of whether a nonprescription sunscreen a
Release date- 21112015- Genentech, a member of the Roche Group, today announced data from the pivotal coBRIM study, which showed that Cotellic in combination with Zelboraf helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer than with Zelboraf alone. The final coBRIM OS results were